Advanced

Prophylactic therapy in haemophilia.

Ljung, Rolf LU (2009) In Blood Reviews 23(6). p.267-274
Abstract
Clinical experience since decades and numerous retro- and, recently, also prospective studies clearly demonstrate that prophylactic treatment, albeit much more expensive, is superior to on-demand treatment regardless if outcome focus on number of joint- or life-threatening bleeds or arthropathy, evaluated by X-ray or MRI, or quality of life measured by general or hemophilia specific instruments. Optimal prophylactic treatment should be started early (primary prophylaxis) but various opinions exist on the dose and dose interval, depending on the objective of treatment in the individual patient which in turn is usually dependent on the resources in the health care system. Secondary prophylaxis, started later in childhood or in adults is... (More)
Clinical experience since decades and numerous retro- and, recently, also prospective studies clearly demonstrate that prophylactic treatment, albeit much more expensive, is superior to on-demand treatment regardless if outcome focus on number of joint- or life-threatening bleeds or arthropathy, evaluated by X-ray or MRI, or quality of life measured by general or hemophilia specific instruments. Optimal prophylactic treatment should be started early (primary prophylaxis) but various opinions exist on the dose and dose interval, depending on the objective of treatment in the individual patient which in turn is usually dependent on the resources in the health care system. Secondary prophylaxis, started later in childhood or in adults is beneficial but less cost-effective. This review covers proof of concept of primary prophylaxis in children and secondary prophylaxis in adults, comparisons between prophylaxis and on demand treatment as well as outcome measurers, health economics and future trends of prophylactic treatment of hemophilia. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Blood Reviews
volume
23
issue
6
pages
267 - 274
publisher
Churchill Livingstone
external identifiers
  • wos:000271804200005
  • pmid:19775786
  • scopus:70349961526
ISSN
1532-1681
DOI
10.1016/j.blre.2009.08.001
language
English
LU publication?
yes
id
f2b19847-e504-4987-98c1-cf2335f2e2fe (old id 1483225)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19775786?dopt=Abstract
date added to LUP
2012-01-18 13:58:42
date last changed
2017-11-12 03:32:31
@article{f2b19847-e504-4987-98c1-cf2335f2e2fe,
  abstract     = {Clinical experience since decades and numerous retro- and, recently, also prospective studies clearly demonstrate that prophylactic treatment, albeit much more expensive, is superior to on-demand treatment regardless if outcome focus on number of joint- or life-threatening bleeds or arthropathy, evaluated by X-ray or MRI, or quality of life measured by general or hemophilia specific instruments. Optimal prophylactic treatment should be started early (primary prophylaxis) but various opinions exist on the dose and dose interval, depending on the objective of treatment in the individual patient which in turn is usually dependent on the resources in the health care system. Secondary prophylaxis, started later in childhood or in adults is beneficial but less cost-effective. This review covers proof of concept of primary prophylaxis in children and secondary prophylaxis in adults, comparisons between prophylaxis and on demand treatment as well as outcome measurers, health economics and future trends of prophylactic treatment of hemophilia.},
  author       = {Ljung, Rolf},
  issn         = {1532-1681},
  language     = {eng},
  number       = {6},
  pages        = {267--274},
  publisher    = {Churchill Livingstone},
  series       = {Blood Reviews},
  title        = {Prophylactic therapy in haemophilia.},
  url          = {http://dx.doi.org/10.1016/j.blre.2009.08.001},
  volume       = {23},
  year         = {2009},
}